Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

被引：1
|
作者：
Miyauchi, Eisaku
Morita, Satoshi
Nakamura, Atsushi
Hosomi, Yukio
Watanabe, Kana
Ikeda, Satoshi
Seike, Masahiro
Fujita, Yuka
Minato, Koichi
Ko, Ryo
Harada, Toshiyuki
Hagiwara, Koichi
Kobayashi, Kunihiko
Nukiwa, Toshihiro
Inoue, Akira
机构：
[1] Tohoku Univ Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[3] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan
[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[5] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[6] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
[7] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan
[8] Natl Hosp Org, Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Hokkaido, Japan
[9] Gunma Prefectural Canc Ctr, Dept Resp Med, Ota, Japan
[10] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[11] JCHO Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[12] Jichi Med Univ, Div Pulm Med, Dept Internal Med, Shimotsuke, Tochigi, Japan
[13] Saitama Med Univ, Int Med Ctr, Dept Pulm Med, Hidaka, Japan
[14] Tohoku Univ, Dept Resp Med, Sendai, Miyagi, Japan
[15] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9081
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3587 - +
  • [2] Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
    Hosomi, Yukio
    Morita, Satoshi
    Sugawara, Shunichi
    Kato, Terufumi
    Fukuhara, Tatsuro
    Gemma, Akihiko
    Takahashi, Kazuhisa
    Fujita, Yuka
    Harada, Toshiyuki
    Minato, Koichi
    Takamura, Kei
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    Kudoh, S.
    Nagao, K.
    Nakai, Y.
    Yoshioka, T.
    Harada, M.
    Isobe, T.
    Kasai, T.
    Oizumi, S.
    Kamimura, M.
    Watanabe, S.
    Okamoto, H.
    Shingyoji, M.
    Osaki, Y.
    Hasegawa, Y.
    Koyama, S.
    Isobe, H.
    Morikawa, N.
    Ishida, T.
    Ishii, Y.
    Takiguchi, Y.
    Watanabe, H.
    Kurokawa, H.
    Sunaga, N.
    Mori, Y.
    Tabata, T.
    Nakagawa, T.
    Kuyama, S.
    Kiura, K.
    Usui, K.
    Soejima, K.
    Nishitsuji, M.
    Kinoshita, I
    Taima, K.
    Nishimura, N.
    Kishi, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 115 - +
  • [3] Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
    Seike, M.
    Inoue, A.
    Sugawara, S.
    Morita, S.
    Hosomi, Y.
    Ikeda, S.
    Watanabe, K.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 496 - 496
  • [4] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2380 - 2388
  • [5] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [6] Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
    Nakamura, Atsushi
    Inoue, Akira
    Morita, Satoshi
    Hosomi, Yukio
    Kato, Terufumi
    Fukuhara, Tatsuro
    Gemma, Akihiko
    Takahashi, Kazuhisa
    Fujita, Yuka
    Harada, Toshiyuki
    Minato, Koichi
    Takamura, Kei
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] QOL ANALYSIS FROM NEJ 002 STUDY COMPARING GEFITINIB TO CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER WITH MUTATED EGFR
    Yoshizawa, H.
    Kobayashi, K.
    Inoue, A.
    Maemondo, M.
    Sugawara, S.
    Oizumi, S.
    Gemma, A.
    Morita, S.
    Hagiwara, K.
    Nukiwa, T.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 122 - 122
  • [8] NEJ009 trial: A randomized phase III study of gefitinib (G) on combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation
    Inoue, Akira
    Hosomi, Yukio
    Maemondo, Makoto
    Sugawara, Shunichi
    Kato, Terufumi
    Takahashi, Kazuhlsa
    Fujita, Yuka
    Gamma, Aklhlko
    Harada, Toshiyuki
    Oizumi, Satoshi
    Minato, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
    Noronha, Vanita
    Patil, Vijay Maruti
    Joshi, Amit
    Menon, Nandini
    Chougule, Anuradha
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajiv
    More, Sucheta
    Goud, Supriya
    Kadam, Nandkumar
    Daware, Nilesh
    Bhattacharjee, Atanu
    Shah, Srushti
    Yadav, Akanksha
    Trivedi, Vaishakhi
    Behel, Vichitra
    Dutt, Amit
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 124 - +
  • [10] Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer: A meta analysis
    Yi, Min
    He, Ting
    Wang, Kaijin
    Wei, Yonggang
    [J]. CLINICS, 2023, 78
12345